LivaNova PLC (NASDAQ:LIVN) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of LivaNova PLC (NASDAQ:LIVN) have been assigned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $69.3750.

A number of equities analysts have recently issued reports on LIVN shares. Mizuho increased their price objective on shares of LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Barclays increased their target price on LivaNova from $58.00 to $67.00 and gave the company an “equal weight” rating in a research report on Friday. Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Stifel Nicolaus raised their price objective on LivaNova from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Finally, KeyCorp started coverage on LivaNova in a research note on Friday, December 19th. They issued an “overweight” rating and a $81.00 target price on the stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Amundi raised its holdings in shares of LivaNova by 7.2% in the first quarter. Amundi now owns 196,435 shares of the company’s stock worth $7,362,000 after buying an additional 13,142 shares during the last quarter. New York State Common Retirement Fund increased its position in shares of LivaNova by 79.6% in the 2nd quarter. New York State Common Retirement Fund now owns 86,741 shares of the company’s stock valued at $3,905,000 after acquiring an additional 38,451 shares during the period. Harbor Capital Advisors Inc. raised its stake in LivaNova by 20.3% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 102,165 shares of the company’s stock worth $4,599,000 after acquiring an additional 17,252 shares during the last quarter. Aberdeen Group plc lifted its position in LivaNova by 18.1% during the 2nd quarter. Aberdeen Group plc now owns 326,786 shares of the company’s stock worth $14,712,000 after acquiring an additional 50,076 shares during the period. Finally, EP Wealth Advisors LLC purchased a new stake in LivaNova during the 1st quarter valued at about $293,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Stock Down 0.8%

Shares of LivaNova stock opened at $64.41 on Wednesday. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.33 and a quick ratio of 1.12. The stock has a market cap of $3.52 billion, a price-to-earnings ratio of -16.10 and a beta of 0.97. The firm’s 50-day moving average is $60.10 and its two-hundred day moving average is $54.14. LivaNova has a 1 year low of $32.48 and a 1 year high of $65.57.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.